Akari Therapeutics, Plc
AKTX
$1.40
-$0.03-2.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.71% | -18.10% | -15.35% | -8.15% | -16.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.27% | 4.26% | -9.87% | -18.88% | -27.21% |
| Operating Income | -5.27% | -4.26% | 9.87% | 18.88% | 27.21% |
| Income Before Tax | -97.75% | -116.37% | -103.56% | -43.25% | 43.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -97.75% | -116.37% | -103.56% | -43.25% | 43.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.75% | -116.37% | -103.56% | -43.25% | 43.61% |
| EBIT | -5.27% | -4.26% | 9.87% | 18.88% | 27.21% |
| EBITDA | -5.21% | -4.21% | 9.92% | 18.94% | 27.21% |
| EPS Basic | -1.50% | -33.82% | -23.63% | 14.61% | 65.34% |
| Normalized Basic EPS | 15.23% | -20.05% | -15.71% | 14.61% | 65.35% |
| EPS Diluted | -1.32% | -33.60% | -23.46% | 14.69% | 65.28% |
| Normalized Diluted EPS | 15.37% | -19.85% | -15.55% | 14.69% | 65.29% |
| Average Basic Shares Outstanding | 161.59% | 89.53% | 63.77% | 56.84% | 46.19% |
| Average Diluted Shares Outstanding | 166.29% | 89.41% | 63.64% | 57.58% | 45.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |